Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126191761 | 12619176 | 1 | I | 201505 | 20160714 | 20160803 | 20160803 | PER | US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49461YA | BOEHRINGER INGELHEIM | 85.71 | YR | M | Y | 0.00000 | 20160803 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126191761 | 12619176 | 1 | PS | FLOMAX | TAMSULOSIN HYDROCHLORIDE | 1 | Unknown | Y | 20579 | ||||||||||
126191761 | 12619176 | 2 | SS | XTANDI | ENZALUTAMIDE | 1 | Oral | 160 ANZ | 0 | CAPSULE | QID | ||||||||
126191761 | 12619176 | 3 | C | TAMIFLU | OSELTAMIVIR PHOSPHATE | 1 | Unknown | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126191761 | 12619176 | 1 | Product used for unknown indication |
126191761 | 12619176 | 2 | Prostate cancer |
126191761 | 12619176 | 3 | Product used for unknown indication |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126191761 | 12619176 | Fall | |
126191761 | 12619176 | Micturition urgency | |
126191761 | 12619176 | Penis disorder | |
126191761 | 12619176 | Urinary incontinence |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126191761 | 12619176 | 2 | 20141202 | 0 |